Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA, Stanzel S, Patre M, Ellis PA.

Open source

DOI
10.1186/s12885-019-5687-0
Published
2019-05-30
Container
BMC Cancer
Publisher
Figshare
Open access
yes

Credibility signals

uncertain Score 61/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12885-019-5687-0,
  title = {Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.},
  author = {Perez EA and  de Haas SL and  Eiermann W and  Barrios CH and  Toi M and  Im YH and  Conte PF and  Martin M and  Pienkowski T and  Pivot XB and  Burris HA and  Stanzel S and  Patre M and  Ellis PA.},
  year = {2019},
  journal = {BMC Cancer},
  doi = {10.1186/s12885-019-5687-0},
  url = {https://doi.org/10.1186/s12885-019-5687-0}
}

RIS

TY  - JOUR
TI  - Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
AU  - Perez EA
AU  -  de Haas SL
AU  -  Eiermann W
AU  -  Barrios CH
AU  -  Toi M
AU  -  Im YH
AU  -  Conte PF
AU  -  Martin M
AU  -  Pienkowski T
AU  -  Pivot XB
AU  -  Burris HA
AU  -  Stanzel S
AU  -  Patre M
AU  -  Ellis PA.
PY  - 2019
JO  - BMC Cancer
DO  - 10.1186/s12885-019-5687-0
UR  - https://doi.org/10.1186/s12885-019-5687-0
ER  - 

APA

EA, P., SL, D. H., W, E., CH, B., M, T., YH, I., PF, C., M, M., T, P., XB, P., HA, B., S, S., M, P., & PA., E. (2019). Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.. BMC Cancer. https://doi.org/10.1186/s12885-019-5687-0

Source records